Time to Target Uric Acid to Retard Chronic Kidney Disease Progression

Area of Science:

• Nephrology
• Urology
• Biochemistry

Background:

• Serum uric acid (UA) elevation is linked to chronic kidney disease (CKD) incidence and progression.
• Previous meta-analyses have not confirmed urate-lowering therapy benefits for CKD progression.
• The optimal target serum UA level for treatment remains debated.

Purpose of the Study:

• To review recent findings on the causal relationship between serum UA and kidney injury.
• To discuss the role of UA transporters in kidney and intestinal UA handling.
• To explore the link between UA, metabolic syndrome, and kidney disease.

Main Methods:

• Review of observational studies and meta-analyses on UA and CKD.
• Analysis of propensity score data to determine target UA levels.
• Examination of animal models elucidating UA-induced kidney injury mechanisms.
• Discussion of novel urate transporter discoveries (e.g., ABCG2, URAT1).

Main Results:

• Propensity score analysis suggests targeting serum UA below 6.0 mg/dL to prevent end-stage renal disease.
• Animal models show hyperuricemia induces hypertension, arteriolosclerosis, and albuminuria via oxidative stress.
• Intestinal ABCG2 may compensate for reduced renal UA clearance in CKD.
• Insulin influences UA transporters (URAT1, ABCG2) in kidney tubules.

Conclusions:

• Serum UA is a significant risk factor and potential causal agent in kidney injury.
• Understanding UA transport mechanisms offers new insights into CKD pathogenesis.
• Targeting serum UA may be a viable strategy for CKD management, particularly in metabolic syndrome contexts.